delamanid Report issue

Small molecule Experimental
AACT ChEMBL Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Delamanid, sold under the brand name Deltyba, is a medication used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. It is taken by mouth.   Wikipedia

Chemistry

  • SMILES: C[C@]1(COc2ccc(cc2)N3CCC(CC3)Oc4ccc(OC(F)(F)F)cc4)Cn5cc(nc5O1)[N+](=O)[O-]
  • InChIKey: XDAOLTSRNUSPPH-XMMPIXPASA-N
  • Mol. Mass: 534.49
  • ALogP: 4.97
  • ChEMBL Molecule:
    delamanid  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

delamanid | deltyba | opc-67683

Organizations (47)

Research & Development (47)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (1)


 

Tuberculosis

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Acne Vulgaris (Phase 1)

Bacterial Infections (Phase 3)

Extensively Drug-Resistant Tuberculosis (Phase 3)

Gram-Positive Bacterial Infections (Phase 3)

HIV Infections (Phase 4)

Infections (Phase 2)

Tuberculosis (Phase 3)

Tuberculosis, Multidrug-Resistant (Phase 4)

Tuberculosis, Pulmonary (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 25
  • # of Trial Organizations: 47

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue